c-Myc-targeted therapy in breast cancer: A review of fundamentals and pharmacological Insights

•c-Myc is an oncogene, highly expressed in breast cancer (BC).•c-Myc expression is most prevalent in triple-negative breast cancer (TNBC).•c-Myc is linked to several BC hallmarks, including cell proliferation, differentiation, autophagy, apoptosis, and protein biosynthesis.•Natural and synthetic sub...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Gene Ročník 941; s. 149209
Hlavní autori:	Stipp, Maria Carolina, Acco, Alexandra
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier B.V 15.03.2025
Predmet:	angiogenesis Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use apoptosis autophagy Breast cancer therapy breast neoplasms Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism c-Myc Carcinogenesis cell proliferation chromosomal instability clinical trials erbB-2 receptor estrogen receptors Female Gene Expression Regulation, Neoplastic - drug effects genes Humans immune evasion Molecular Targeted Therapy neoplasm progression Oncogene oncogene proteins progesterone receptors protein synthesis Proto-Oncogene Proteins c-myc - antagonists & inhibitors Proto-Oncogene Proteins c-myc - genetics Proto-Oncogene Proteins c-myc - metabolism therapeutics TNBC Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - metabolism PR MDSC HIF-1α HR IL-23 TNM AKT1 DA-EPOCH Anti-PD1 TNBC MMCI AF c-Myc BL1 b/HLD/LZ BL2 BKT p-YAP CDC25C CSF-1 INF-gamma IL-10 IL-6 RB MMP-2 E2f-1 ALOX15 M Carcinogenesis BCSC S62 BAK-1 P CCL-9 IRE1 PD-L1 TGF-β CCL-5 CpG GLUT1 OX-40 XBP1 MSL CDC2 CDK9 BCL-10 STAT CHK1 TAD TIL CDK1 aOX40 LAR BCL2L1 FGFR1 TAM MNK1 OMO-103 PTEN BRCA1 CUDC-907 NF-κB eif4E P27 ALDH1 MRC1 EPOCH MHC-I MYCi975 VIP152 Ki67 MAX45 CD-47 NHE III1 H2S EMT ER MMP9 miR1-17 PANC-1 Ck5/8 TLR9 NK MK-1026 PARP G4 CSC CD-8 CCL2 MAPK1 UNS MICA Brd4 MICB SRC-1 Erk1/2 NCCTG-N9831 RRM1 CDK4/6 EGF VEGF Oncogene TME P53 PI3KCA VEGFA Mcl-1 Breast cancer therapy T58 4E-BP1 HER2 PRKD
ISSN:	0378-1119, 1879-0038, 1879-0038
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!